Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or Melanoma
Stopped early · Phase 1/Phase 2
Conditions studied: Brain and Central Nervous System Tumors, Melanoma, Solid Tumor
In brief
RATIONALE: Drugs used in chemotherapy, temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or stopping them from dividing. Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving temozolomide together with bortezomib may kill more tumor cells. PURPOSE: To determine the best dose of bortezomib and temozolomide and to see how well they work in treating patients with advanced refractory solid tumors or melanoma.
Key facts
- Study ID
- NCT00512798
- Run by
- Vanderbilt-Ingram Cancer Center
- People needed
- 47
- Starts
- 2003-06-01
- Expected to finish
- 2008-03-01
- Last updated by the study team
- 2012-10-02
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Vanderbilt-Ingram Cancer Center — Nashville, Tennessee, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.